These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 22053053)

  • 1. Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua.
    Fryer JD; Yu P; Kang H; Mandel-Brehm C; Carter AN; Crespo-Barreto J; Gao Y; Flora A; Shaw C; Orr HT; Zoghbi HY
    Science; 2011 Nov; 334(6056):690-3. PubMed ID: 22053053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis.
    Crespo-Barreto J; Fryer JD; Shaw CA; Orr HT; Zoghbi HY
    PLoS Genet; 2010 Jul; 6(7):e1001021. PubMed ID: 20628574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes.
    Bowman AB; Lam YC; Jafar-Nejad P; Chen HK; Richman R; Samaco RC; Fryer JD; Kahle JJ; Orr HT; Zoghbi HY
    Nat Genet; 2007 Mar; 39(3):373-9. PubMed ID: 17322884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology.
    Lam YC; Bowman AB; Jafar-Nejad P; Lim J; Richman R; Fryer JD; Hyun ED; Duvick LA; Orr HT; Botas J; Zoghbi HY
    Cell; 2006 Dec; 127(7):1335-47. PubMed ID: 17190598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1.
    Lim J; Crespo-Barreto J; Jafar-Nejad P; Bowman AB; Richman R; Hill DE; Orr HT; Zoghbi HY
    Nature; 2008 Apr; 452(7188):713-8. PubMed ID: 18337722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration.
    Jafar-Nejad P; Ward CS; Richman R; Orr HT; Zoghbi HY
    Proc Natl Acad Sci U S A; 2011 Feb; 108(5):2142-7. PubMed ID: 21245341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model.
    Gehrking KM; Andresen JM; Duvick L; Lough J; Zoghbi HY; Orr HT
    Hum Mol Genet; 2011 Jun; 20(11):2204-12. PubMed ID: 21427130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine disease toxicity is regulated by Nemo-like kinase in spinocerebellar ataxia type 1.
    Ju H; Kokubu H; Todd TW; Kahle JJ; Kim S; Richman R; Chirala K; Orr HT; Zoghbi HY; Lim J
    J Neurosci; 2013 May; 33(22):9328-36. PubMed ID: 23719801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model.
    Watase K; Gatchel JR; Sun Y; Emamian E; Atkinson R; Richman R; Mizusawa H; Orr HT; Shaw C; Zoghbi HY
    PLoS Med; 2007 May; 4(5):e182. PubMed ID: 17535104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1.
    Ju H; Kokubu H; Lim J
    Mol Neurobiol; 2014 Dec; 50(3):866-874. PubMed ID: 24752589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focused cerebellar laser light induced hyperthermia improves symptoms and pathology of polyglutamine disease SCA1 in a mouse model.
    Hearst SM; Shao Q; Lopez M; Raucher D; Vig PJ
    Cerebellum; 2014 Oct; 13(5):596-606. PubMed ID: 24930030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel function of Ataxin-1 in the modulation of PP2A activity is dysregulated in the spinocerebellar ataxia type 1.
    Sánchez I; Piñol P; Corral-Juan M; Pandolfo M; Matilla-Dueñas A
    Hum Mol Genet; 2013 Sep; 22(17):3425-37. PubMed ID: 23630944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of protein complex formation and reconfiguration by polyglutamine disease protein Ataxin-1 and Capicua.
    Kim E; Lu HC; Zoghbi HY; Song JJ
    Genes Dev; 2013 Mar; 27(6):590-5. PubMed ID: 23512657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
    Venkatraman A; Hu YS; Didonna A; Cvetanovic M; Krbanjevic A; Bilesimo P; Opal P
    Hum Mol Genet; 2014 Jul; 23(14):3733-45. PubMed ID: 24594842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1.
    Emir UE; Brent Clark H; Vollmers ML; Eberly LE; Öz G
    J Neurochem; 2013 Dec; 127(5):660-8. PubMed ID: 24032423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy.
    Keiser MS; Boudreau RL; Davidson BL
    Mol Ther; 2014 Mar; 22(3):588-595. PubMed ID: 24419082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis.
    Orr HT
    Prog Neurobiol; 2012 Dec; 99(3):179-85. PubMed ID: 22531670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.
    Zoghbi HY; Orr HT
    J Biol Chem; 2009 Mar; 284(12):7425-9. PubMed ID: 18957430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of the phosphorylation dependent complex formation of neurodegenerative disease protein Ataxin-1 and RBM17.
    Kim E; Lee Y; Choi S; Song JJ
    Biochem Biophys Res Commun; 2014 Jul; 449(4):399-404. PubMed ID: 24858692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism.
    Rousseaux MWC; Tschumperlin T; Lu HC; Lackey EP; Bondar VV; Wan YW; Tan Q; Adamski CJ; Friedrich J; Twaroski K; Chen W; Tolar J; Henzler C; Sharma A; Bajić A; Lin T; Duvick L; Liu Z; Sillitoe RV; Zoghbi HY; Orr HT
    Neuron; 2018 Mar; 97(6):1235-1243.e5. PubMed ID: 29526553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.